Odevixibat Patent Expiration
Odevixibat is used for reducing serum bile acids and treating pruritus in patients with Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis. It was first introduced by Ipsen Biopharmaceuticals Inc
Odevixibat Patents
Given below is the list of patents protecting Odevixibat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bylvay | US11583539 | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors | Nov 12, 2041 | Ipsen |
| Bylvay | US12447156 | Treating Progressive Familial Intrahepatic Cholestasis (Pfic) With Ibat Inhibitors | Nov 12, 2041 | Ipsen |
| Bylvay | US10975046 | Crystal modifications of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US11365182 | Crystal modifications of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US11801226 | Pharmaceutical formulation of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US11802115 | Pharmaceutical formulation of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US12091394 | Crystal modifications of odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US12508234 | Pharmaceutical Formulation Of Odevixibat | Jun 20, 2039 | Ipsen |
| Bylvay | US9694018 | IBAT inhibitors for the treatment of liver disease | Mar 18, 2034 | Ipsen |
| Bylvay | US10011633 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US10093697 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US10487111 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US10981952 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US11732006 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US12187812 | IBAT inhibitors for the treatment of liver diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US12545705 | Ibat Inhibitors For The Treatment Of Liver Diseases | Nov 08, 2031 | Ipsen |
| Bylvay | US7132416 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep 05, 2022
(Expired) | Ipsen |
Odevixibat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Odevixibat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | Albireo, an Ipsen Company | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia | Albireo, an Ipsen Company | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD) | Albireo, an Ipsen Company | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |